Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an announcement.
Shanghai Henlius Biotech, Inc. has announced amendments to the terms of reference for its Nomination Committee, initially established in 2019. The changes emphasize the inclusion of independent non-executive directors and gender diversity within the committee, reflecting the company’s commitment to robust governance and inclusive leadership practices.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development and commercialization of high-quality biologics. The company is known for its innovative approach to biopharmaceuticals, targeting various therapeutic areas to address unmet medical needs.
Average Trading Volume: 1,440,209
Technical Sentiment Signal: Buy
Current Market Cap: HK$27.53B
See more data about 2696 stock on TipRanks’ Stock Analysis page.